Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Chlorpromazine versus placebo for schizophrenia

Open access
Adams, Clive E, Awad, George A, Rathbone, John, Thornley, Ben, Soares-Weiser, Karla·2014·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. OBJECTIVES: To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non-affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. DATA COLLECTION AND ANALYSIS: We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed-effect model. MAIN RESULTS: We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow-up (n = 512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We found chlorpromazine provided a global improvement in a person's symptoms and functioning (n = 1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). Fewer people allocated to chlorpromazine left trials early ( n = 1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n = 1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases a person's chances of experiencing acute movement disorders (n = 942, 5 RCTs, RR 3.47 CI 1.50 to 8.03) and parkinsonism (n = 1468, 15 RCTs, RR 2.11 CI 1.59 to 2.80). Akathisia did not occur more often in the chlorpromazine group than placebo. Chlorpromazine clearly causes a lowering of blood pressure with accompanying dizziness (n = 1488, 18 RCTs, RR 2.38 CI 1.74 to 3.25) and considerable weight gain (n = 165, 5 RCTs, RR 4.92 CI 2.32 to 10.43). AUTHORS' CONCLUSIONS: The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to support clinical impression. Chlorpromazine's global position as a 'benchmark' treatment for psychoses is not threatened by the findings of this review. Chlorpromazine, in common use for half a century, is a well-established but imperfect treatment. Judicious use of this best available evidence should lead to improved evidence-based decision making by clinicians, carers and patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd000284.pub3

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 481

  1. Abrams, 1958, Chlorpromazine in the treatment of chronic schizophrenia, Diseases of the Nervous System, 19, 20
  2. Baker, 1959, A controlled trial of ethylcrotonylurea, British Journal of Psychiatry, 105, 852
  3. Ban, 1975, Comprehensive clinical studies with thiothixene, Diseases of the Nervous System, 36, 473
  4. Bishop, 1963, Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients, American Journal of Psychiatry, 120, 180, 10.1176/ajp.120.2.180 · doi:10.1176/ajp.120.2.180
  5. Borison, 1991, Does sigma receptor antagonism predict clinical antipsychotic efficacy?, Psychopharmacology Bulletin, 27, 103
  6. Borison, 1990, Sigma receptor antagonism and antipsychotic actions in schizophrenic patients, European Journal of Pharmacology, 183, 23, 10.1016/0014-2999(90)93880-Y · doi:10.1016/0014-2999(90)93880-y
  7. Chouinard, 1990, A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation, Acta Psychiatria Scandinavica Supplementum, 358, 111, 10.1111/j.1600-0447.1990.tb05301.x · DOI
  8. Clark, 1961, Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment, Psychopharmacologia, 2, 107, 10.1007/BF00592679 · doi:10.1007/bf00592679
  9. Clark, 1963, Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects, Psychosomatic Medicine, 25, 212, 10.1097/00006842-196305000-00002 · doi:10.1097/00006842-196305000-00002
  10. Ray, 1964, Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment, Journal of Nervous and Mental Diseases, 138, 348, 10.1097/00005053-196404000-00005 · doi:10.1097/00005053-196404000-00005
  11. Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
  12. Clark, 1967, Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships, Psychosomatic Medicine, 29, 634, 10.1097/00006842-196711000-00008 · doi:10.1097/00006842-196711000-00008
  13. Clark, 1968, Evaluation of trifluperidol in chronic schizophrenia, Psychopharmacologia, 12, 193, 10.1007/BF00403773 · doi:10.1007/bf00403773
  14. Clark, 1968, Evaluation of butaperazine in chronic schizophrenia, Clinical Pharmacology and Therapeutics, 97, 57
  15. Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
  16. Clark, 1970, Molindone in chronic schizophrenia, Clinical Pharmacology and Therapeutics, 11, 680, 10.1002/cpt1970115680 · doi:10.1002/cpt1970115680
  17. Serafetinides, 1971, The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine, International Pharmacopsychiatry, 6, 77, 10.1159/000468256 · doi:10.1159/000468256
  18. Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
  19. Clark, 1972, Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships, Archives of General Psychiatry, 27, 479, 10.1001/archpsyc.1972.01750280047009 · doi:10.1001/archpsyc.1972.01750280047009
  20. Clark, 1970, Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships, Psychopharmacologia, 18, 260, 10.1007/BF00412672 · doi:10.1007/bf00412672
  21. Serafetinides, 1972, EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking, Biological Psychiatry, 4, 251
  22. Clark, 1969, Phenothiazines in schizophrenics, Psychopharmacology Bulletin, 6, 37
  23. Clark, 1971, Drug treatment in newly admitted schizophrenic patients, Archives of General Psychiatry, 25, 404, 10.1001/archpsyc.1971.01750170020004 · doi:10.1001/archpsyc.1971.01750170020004
  24. Clark, 1972, Evaluation of loxapine succinate in chronic schizophrenia, Diseases of the Nervous System, 33, 783
  25. Serafetinides, 1971, The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects, International Pharmacopsychiatry, 6, 38, 10.1159/000468249 · doi:10.1159/000468249
  26. Clark, 1977, Evaluation of butaclamol in chronic schizophrenic patients, Journal of Clinical Pharmacology, 17, 529, 10.1002/j.1552-4604.1977.tb05646.x · doi:10.1002/j.1552-4604.1977.tb05646.x
  27. Cohen, 1968, Family interaction patterns, drug treatment, and change in social aggression, Archives of General Psychiatry, 19, 50, 10.1001/archpsyc.1968.01740070052008 · doi:10.1001/archpsyc.1968.01740070052008
  28. Graupner, 1972, Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments, Psychopharmacologia, 27, 343, 10.1007/BF00429387 · doi:10.1007/bf00429387
  29. Cole, 1964, Phenothiazine treatment in acute schizophrenia, Archives of General Psychiatry, 10, 246, 10.1001/archpsyc.1964.01720210028005 · DOI · Paper page
  30. Goldberg, 1965, Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment, British Journal of Psychiatry, 111, 120, 10.1192/bjp.111.471.120 · DOI
  31. Goldberg, 1968, Schizophrenic subtypes defined by response to drugs and placebo, Diseases of the Nervous System, 29, 153
  32. Cooper SJ Raniwalla J Welch C Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia Melbourne, Australia 1996 · doi:10.1016/0924-977x(96)87990-9
  33. Cooper, 2000, A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia, Acta Psychiatrica Scandinavica, 101, 218, 10.1034/j.1600-0447.2000.101003218.x · DOI
  34. Dean, 1958, Schizophrenia treated with and without chlorpromazine, Rocky Mountain Medical Journal, 55, 47
  35. Engelhardt, 1964, Phenothiazines in prevention of psychiatric hospitalization, Archives of General Psychiatry, 11, 162, 10.1001/archpsyc.1964.01720260056007 · doi:10.1001/archpsyc.1964.01720260056007
  36. Engelhardt, 1960, Prevention of psychiatric hospitalization with use of psychopharmacological agents, JAMA, 173, 147, 10.1001/jama.1960.03020200019005 · doi:10.1001/jama.1960.03020200019005
  37. Engelhardt, 1969, Physician bias and the double-blind, Archives of General Psychiatry, 20, 315, 10.1001/archpsyc.1969.01740150059009 · DOI
  38. Engelhardt, 1963, Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure, JAMA, 186, 981, 10.1001/jama.1963.03710110033006 · doi:10.1001/jama.1963.03710110033006
  39. Engelhardt, 1967, Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation, Archives of General Psychiatry, 16, 98, 10.1001/archpsyc.1967.01730190100013 · DOI
  40. Freedman, 1967, On the modification of paranoid symptomatology, Journal of Nervous and Mental Disease, 144, 29, 10.1097/00005053-196701000-00006 · doi:10.1097/00005053-196701000-00006
  41. Freedman, 1970, On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines, Journal of Nervous and Mental Disease, 150, 68, 10.1097/00005053-197001000-00008 · doi:10.1097/00005053-197001000-00008
  42. Rosen, 1968, The hospitalization proneness scale as a predictor of response to phenothiazine treatment, Journal of Nervous and Mental Disease, 6, 476, 10.1097/00005053-196806000-00007 · doi:10.1097/00005053-196806000-00007
  43. Belmont, 1963, The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses, Journal of Nervous and Mental Disease, 137, 42, 10.1097/00005053-196307000-00004 · doi:10.1097/00005053-196307000-00004
  44. Fink, 1963, Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns, Neuropsychopharmacology, 3, 370
  45. Klein, 1967, Importance of psychiatric diagnosis in prediction of clinical drug effects, Archives of General Psychiatry, 16, 118, 10.1001/archpsyc.1967.01730190120016 · DOI · Paper page
  46. Klein, 1968, Psychiatric diagnosis and a typology of clinical drug effects, Psychopharmacologia, 13, 359, 10.1007/BF00404952 · DOI
  47. Klein, 1968, Prediction of drug effect by diagnostic decision tree, Diseases of the Nervous System, 29, 159
  48. Levenstein, 1966, Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years, American Journal of Psychiatry, 122, 1102, 10.1176/ajp.122.10.1102 · DOI
  49. Fleming, 1959, A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis, British Journal of Psychiatry, 105, 349
  50. Grygier, 1958, Chlorpromazine used with an intensive occupational therapy program. A.M.A, Archives of Neurology and Psychiatry, 79, 697, 10.1001/archneurpsyc.1958.02340060095013 · doi:10.1001/archneurpsyc.1958.02340060095013
  51. Gwynne, 1962, Efficacy of trifluoperazine on withdrawal in chronic schizophrenia, Journal of Nervous and Mental Disease, 134, 451, 10.1097/00005053-196205000-00008 · doi:10.1097/00005053-196205000-00008
  52. Hall, 1955, A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics, Journal of Nervous and Mental Disease, 122, 301, 10.1097/00005053-195510000-00001 · doi:10.1097/00005053-195510000-00001
  53. Hollister, 1966, Phenothiazine derivatives and morphologic changes in the liver, American Journal of Psychiatry, 123, 211, 10.1176/ajp.123.2.211 · doi:10.1176/ajp.123.2.211
  54. Hamill, 1975, The immediate effects of chlorpromazine in newly admitted schizophrenic patients, American Journal of Psychiatry, 132, 1023, 10.1176/ajp.132.10.1023 · doi:10.1176/ajp.132.10.1023
  55. Hamilton, 1960, A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics, British Journal of Psychiatry, 106, 40
  56. Hankoff, 1962, A reference study of ataraxics. A two-week double blind outpatient evaluation, Journal of New Drugs, 2, 173, 10.1177/009127006200200305 · doi:10.1177/009127006200200305
  57. Hine, 1958, Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic, Journal of Nervous and Mental Diseases, 127, 220, 10.1097/00005053-195809000-00002 · doi:10.1097/00005053-195809000-00002
  58. Goldberg, 1977, Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy, Archives of General Psychiatry, 34, 171, 10.1001/archpsyc.1977.01770140061008 · DOI · Paper page
  59. Hogarty, 1973, Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates, Archives of General Psychiatry, 28, 54, 10.1001/archpsyc.1973.01750310038007 · DOI · Paper page
  60. Hogarty, 1974, Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients, Archives of General Psychiatry, 31, 609, 10.1001/archpsyc.1974.01760170011002 · DOI · Paper page
  61. Hogarty, 1974, Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates, Archives of General Psychiatry, 31, 603, 10.1001/archpsyc.1974.01760170005001 · DOI · Paper page
  62. Hogarty, 1977, Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients, Archives of General Psychiatry, 34, 297, 10.1001/archpsyc.1977.01770150055005 · DOI · Paper page
  63. Hogarty, 1984, Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate, Journal of Clinical Psychopharmacology, 4, 17, 10.1097/00004714-198402000-00003 · doi:10.1097/00004714-198402000-00003
  64. Klein, 1973, Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients, Archives of General Psychiatry, 29, 480, 10.1001/archpsyc.1973.04200040034006 · doi:10.1001/archpsyc.1973.04200040034006
  65. Kurland, 1961, The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness, Journal of Nervous and Mental Disease, 133, 1, 10.1097/00005053-196107000-00001 · doi:10.1097/00005053-196107000-00001
  66. Kurland, 1961, Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations, Journal of Nervous and Mental Disease, 132, 61, 10.1097/00005053-196101000-00010 · doi:10.1097/00005053-196101000-00010
  67. Kurland, 1959, Pre-admission drug treatment of state psychiatric hospital patients, American Journal of Psychiatry, 115, 1028, 10.1176/ajp.115.11.1028 · doi:10.1176/ajp.115.11.1028
  68. Kurland, 1960, The phenothiazine tranquilizers - their neurological complications and significance, Psychosomatics, 1, 192, 10.1016/S0033-3182(60)72984-0 · doi:10.1016/s0033-3182(60)72984-0
  69. Letemendia, 1967, Chlorpromazine and the untreated chronic schizophrenic: a long-term trial, British Journal of Psychiatry, 113, 950, 10.1192/bjp.113.502.950 · doi:10.1192/bjp.113.502.950
  70. Nishikawa, 1982, Prophylactic effect of neuroleptics in symptom-free schizophrenics, Psychopharmacology, 77, 301, 10.1007/BF00432759 · DOI
  71. Payne, 1960, A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients, Manitoba Medical Review, 196
  72. Peet, 1981, Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo, British Journal of Psychiatry, 139, 105, 10.1192/bjp.139.2.105 · DOI
  73. Crane, 1968, Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs, Agressologie, 2, 209
  74. Long, 1968, Incidence and significance of chlorpromazine-induced eye changes, Diseases of the Nervous System, 29, 19
  75. Gardos, 1982, A 12-year follow-up study of chronic schizophrenics, Hospital and Community Psychiatry, 33, 983
  76. Mandel, 1968, Agranulocyctosis and phenothiazines, Diseases of the Nervous System, 29, 32
  77. Prien, 1968, High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group, Archives of General Psychiatry, 18, 482, 10.1001/archpsyc.1968.01740040098013 · doi:10.1001/archpsyc.1968.01740040098013
  78. Prien, 1970, Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study, Archives of General Psychiatry, 23, 464, 10.1001/archpsyc.1970.01750050080011 · doi:10.1001/archpsyc.1970.01750050080011
  79. Prien, 1968, Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication, British Journal of Psychiatry, 115, 679, 10.1192/bjp.115.523.679 · DOI
  80. Prien, 1970, Indications for high dose chlorpromazine therapy in chronic schizophrenia, Diseases of the Nervous System, 31, 739
  81. Ramu, 1999, A double blind controlled study on the role of brahmyadiyoga and tagara in navonmada (acute schizophrenia), 59
  82. Ramu, 1999, A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia), 77
  83. Rappaport, 1978, Are there schizophrenics for whom drugs may be unnecessary or contraindicated?, International Pharmacopsychiatry, 13, 100, 10.1159/000468327 · DOI
  84. Reardon, 1966, Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo), Diseases of the Nervous System, 27, 265
  85. Reschke, 1974, Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia, Diseases of the Nervous System, 35, 112
  86. Saretsky, 1966, Effects of chlorpromazine on primary-process thought manifestations, Journal of Abnormal Psychology, 71, 247, 10.1037/h0023595 · doi:10.1037/h0023595
  87. Schiele, 1961, A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients, Journal of Clinical and Experiemental Psychopathology, 22, 151
  88. Serafetinides, 1973, Psychological effects of single dose antipsychotic medication, Biological Psychiatry, 7, 263
  89. Serafetinides, 1972, Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives, Journal of Nervous and Mental Diseases, 154, 31, 10.1097/00005053-197201000-00005 · DOI
  90. Serafetinides, 1973, A method of quantifying EEG for psychopharmacological research, International Pharmacopsychiatry, 8, 245, 10.1159/000468000 · doi:10.1159/000468000
  91. Serafetinides, 1972, Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics, Journal of Nervous and Mental Diseases, 155, 366, 10.1097/00005053-197211000-00010 · DOI
  92. Shepherd, 1956, A controlled clinical study of chlorpromazine and reserpine, Journal of Neurology, Neurosurgery and Psychiatry, 19, 232, 10.1136/jnnp.19.3.232 · DOI
  93. Simon, 1965, Long-term follow-up study of schizophrenic patients, Archives of General Psychiatry, 12, 510, 10.1001/archpsyc.1965.01720350078010 · DOI
  94. Simon, 1958, A controlled study of the short-term differential treatment of schizophrenia, American Journal of Psychiatry, 114, 1077, 10.1176/ajp.114.12.1077 · doi:10.1176/ajp.114.12.1077
  95. Smith, 1961, A clinical study of chlorpromazine and chlordiazepoxide, Connecticut State Medical Journal, 25, 153
  96. Somerville, 1960, Phenothiazine side-effects. Comparison of two major tranquillizers, British Journal of Psychiatry, 106, 1417
  97. Spohn, 1977, Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics, Archives of General Psychiatry, 34, 633, 10.1001/archpsyc.1977.01770180019001 · DOI · Paper page
  98. Tetreault, 1969, Comparative study of two drugs and a placebo in chronic schizophrenia, Actualites Pharmacologiques, 22, 221
  99. Tetreault, 1969, Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients, Diseases of the Nervous System, 30, 74
  100. Vaughan, 1955, Chlorpromazine in psychiatry, Lancet, 1, 1083, 10.1016/S0140-6736(55)90587-0 · doi:10.1016/s0140-6736(55)90587-0
  101. Walsh, 1959, The relative efficacy of "Vespral" and chlorpromazine in the treatment of a group of chronic schizophrenic patients, British Journal of Psychiatry, 105, 199
  102. Weckowicz, 1960, Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients, Diseases of the Nervous System, 21, 527
  103. Xiong, 1994, A double-blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics, Medical Journal of Chinese Civil Administration, 6, 160
  104. Abse, 1960, Evaluation of tranquilizing drugs in the management of acute mental disturbance, American Journal of Psychiatry, 117, 973, 10.1176/ajp.116.11.973 · doi:10.1176/ajp.116.11.973
  105. Acker, 1965, An exploration of the autonomic effects of phenothiazines, Psychopharmacologia, 7, 150, 10.1007/BF00403638 · doi:10.1007/bf00403638
  106. Affleck, 1966, The action of a medication and the physician's expectations, Nebraska State Medical Journal, 51, 331
  107. Agarwal, 1985, Role of ECT phenothiazine combination in schizophrenia, Indian Journal of Psychiatry, 27, 233
  108. Akimoto, 1966, Current status of pharmacotherapy in schizophrenia, Folia Psychiatrica et Neurologica Japonica, 20, 1
  109. Alpert, 1966, Evaluation of treatment with recorded interviews, American Journal of Psychiatry, 122, 1258, 10.1176/ajp.122.11.1258 · doi:10.1176/ajp.122.11.1258
  110. Alpert, 1978, Paradoxical reaction to L-dopa in schizophrenic patients, American Journal of Psychiatry, 135, 1329, 10.1176/ajp.135.11.1329 · doi:10.1176/ajp.135.11.1329
  111. Alson, 1964, The use of adjective check lists with psychotic patients: the problem of pseudo-responses, Journal of Clinical Psychology, 20, 462, 10.1002/1097-4679(196410)20:4<462::AID-JCLP2270200415>3.0.CO;2-V · doi:10.1002/1097-4679(196410)20:4<462::aid-jclp2270200415>3.0.co;2-v
  112. Aman, 1985, Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment, Journal of Mental Deficiency Research, 29, 187
  113. Amin, 1977, A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients, Psychopharmacology Bulletin, 13, 20
  114. Ananth, 1972, Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study, Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie, 5, 406
  115. Andrews, 1976, A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients, British Journal of Psychiatry, 128, 451, 10.1192/bjp.128.5.451 · DOI
  116. Ashcroft, 1961, A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia, Journal of Mental Science (British Journal of Psychiatry from 1963), 107, 287
  117. Ayers, 1984, Subjective response to antipsychotic drugs: failure to replicate predictions of outcome, Journal of Clinical Psychopharmacology, 4, 89, 10.1097/00004714-198404020-00005 · doi:10.1097/00004714-198404020-00005
  118. Azima, 1954, Effects of Largactil in mental syndomes, Canadian Medical Association Journal, 71, 116
  119. Bagadia, 1981, Evaluation of cognitive effects of ECT: preliminary observations, Indian Journal of Psychiatry, 23, 324
  120. Ban, 1977, Negative findings with megavitamins in schizophrenic patients - preliminary report, Communications in Psychopharmacology, 1, 119
  121. Hoffer, 1975, Megavitamin treatment of schizophrenia, Canadian Psychiatric Association Journal, 20, 492, 10.1177/070674377502000621 · doi:10.1177/070674377502000621
  122. Beech, 1990, The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition', Personality and Individual Differences, 11, 1141, 10.1016/0191-8869(90)90026-N · DOI
  123. Benaim, 1960, The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation, Journal of Mental Science, 106, 317, 10.1192/bjp.106.442.317 · doi:10.1192/bjp.106.442.317
  124. Bennett, 1956, Clinical investigation of chlorpromazine and reserpine in private psychiatric practice, American Journal of Psychiatry, 112, 782, 10.1176/ajp.112.10.782 · doi:10.1176/ajp.112.10.782
  125. Blumberg, 1964, Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure, Journal of Psychiatric Research, 2, 51, 10.1016/0022-3956(64)90029-9 · doi:10.1016/0022-3956(64)90029-9
  126. Blumberg, 1969, Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients, Clinical Pharmacology and Therapeutics, 10, 350, 10.1002/cpt1969103350 · DOI
  127. Boullin, 1975, Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine, British Journal of Clinical Pharmacology, 2, 29, 10.1111/j.1365-2125.1975.tb00468.x · DOI
  128. Bowes, 1956, The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital, American Journal of Psychiatry, 113, 530, 10.1176/ajp.113.6.530 · doi:10.1176/ajp.113.6.530
  129. Bressler, 1971, A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population, Psychosomatics, 12, 275, 10.1016/S0033-3182(71)71519-9 · doi:10.1016/s0033-3182(71)71519-9
  130. Brizer, 1985, Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia, American Journal of Psychiatry, 142, 1106, 10.1176/ajp.142.9.1106 · doi:10.1176/ajp.142.9.1106
  131. Burnett, 1975, The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial, Diseases of the Nervous System, 36, 625
  132. Cabrera Gomez, 1994, Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon, Biotherapy, 7, 27, 10.1007/BF01878151 · doi:10.1007/bf01878151
  133. Caffey, 1963, Phenothiazine excretion in chronic schizophrenics, American Journal of Psychiatry, 120, 578, 10.1176/ajp.120.6.578 · doi:10.1176/ajp.120.6.578
  134. Caffey, 1964, Discontinuation or reduction of chemotherapy in chronic schizophrenics, Journal of Chronic Diseases, 17, 347, 10.1016/0021-9681(64)90075-X · DOI
  135. Caffey, 1975, Practical considerations on treatment with antipsychotic preparations, Zhurnal Nevropatologii i Psikhiatrii, 75, 1399
  136. Campbell, 1972, Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick, Current Therapeutic Research, 14, 759
  137. Campbell, 1970, Thiothixene in young disturbed children. A pilot study, Archives of General Psychiatry, 23, 70, 10.1001/archpsyc.1970.01750010072013 · DOI
  138. Cardone, 1969, Chlorpromazine and body image. Effects on chronic schizophrenics, Archives of General Psychiatry, 20, 576, 10.1001/archpsyc.1969.01740170080012 · doi:10.1001/archpsyc.1969.01740170080012
  139. Casey, 1960, Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo, Archives of General Psychiatry, 2, 210, 10.1001/archpsyc.1960.03590080086012 · DOI
  140. Casey, 1961, Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine, American Journal of Psychiatry, 117, 997, 10.1176/ajp.117.11.997 · doi:10.1176/ajp.117.11.997
  141. Chacon, 1973, Clinical and work performance variables in phenothiazine therapy of schizophrenia, Acta Psychiatrica Scandinavica, 49, 65, 10.1111/j.1600-0447.1973.tb04399.x · doi:10.1111/j.1600-0447.1973.tb04399.x
  142. Chacon, 1972, Work study in the assessment of the effects of phenothiazines in schizophrenia, Comprehensive Psychiatry, 13, 549, 10.1016/0010-440X(72)90055-7 · doi:10.1016/0010-440x(72)90055-7
  143. Childers, 1961, A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia, American Journal of Psychiatry, 118, 552, 10.1176/ajp.118.6.552 · doi:10.1176/ajp.118.6.552
  144. Chouinard, 1977, Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit, Journal of Clinical Pharmacology, 17, 162, 10.1002/j.1552-4604.1977.tb04602.x · doi:10.1002/j.1552-4604.1977.tb04602.x
  145. Chouinard-G, 1983, Fluspirilene in the treatment of newly admitted schizophrenic patients, Psychopharmacology Bulletin., 19, 136
  146. Claghorn, 1983, The current status of clozapine, Psychopharmacology Bulletin, 19, 138
  147. Clark, 1970, Ocular pigment deposits: drug-induced false-positives, JAMA, 214, 2339, 10.1001/jama.1970.03180130071025 · doi:10.1001/jama.1970.03180130071025
  148. Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
  149. Clark, 1976, A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients, 191
  150. Clark, 1975, A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients, Psychopharmacology Bulletin, 11, 28
  151. Clark, 1978, Chlorpromazine kinetics and clinical response, Psychopharmacology Bulletin, 14, 43
  152. Cobb, 1956, Changes in the electroencephalogram, the electrodermogram, and the electromyogram provoked by chlorpromazine in man, Abstracts of World Medicine, 20, 177
  153. Cole, 1967, Differences in clinical effects of three phenothiazines in "acute" schizophrenia, Diseases of the Nervous System, 28, 369
  154. Coons, 1962, Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients, Canadian Psychiatric Association Journal, 7, 159, 10.1177/070674376200700403 · doi:10.1177/070674376200700403
  155. Cowden, 1956, Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients, American Journal of Psychiatry, 4, 898, 10.1176/ajp.112.11.898 · DOI
  156. Crane, 1970, High doses of trifluperazine and tardive dyskinesia, Archives of Neurology, 22, 176, 10.1001/archneur.1970.00480200082009 · doi:10.1001/archneur.1970.00480200082009
  157. Crane, 1971, Persistence of neurological symptoms due to neuroleptic drugs, American Journal of Psychiatry, 127, 1407, 10.1176/ajp.127.10.1407 · doi:10.1176/ajp.127.10.1407
  158. Crow, 1986, The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment, British Journal of Psychiatry, 148, 120, 10.1192/bjp.148.2.120 · DOI · Paper page
  159. Johnstone, 1986, The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission, British Journal of Psychiatry, 148, 115, 10.1192/bjp.148.2.115 · DOI · Paper page
  160. MacMillan, 1986, The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients, British Journal of Psychiatry, 148, 128, 10.1192/bjp.148.2.128 · DOI
  161. Curry, 1972, Double-blind trial of fluphenazine decanoate, Lancet, 2, 543, 10.1016/S0140-6736(72)91943-5 · doi:10.1016/s0140-6736(72)91943-5
  162. Cutler, 1957, Effects of "tranquilizers" upon pathological activity in psychotic patients: II. Reserpine, Archives of Neurology and Psychiatry, 78, 61, 10.1001/archneurpsyc.1957.02330370075012 · doi:10.1001/archneurpsyc.1957.02330370075012
  163. Dally, 1966, Treatment and outcome of anorexia nervosa, British Medical Journal, 2, 793, 10.1136/bmj.2.5517.793 · DOI
  164. Danion, 1992, Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers, Psychopharmacology, 108, 345, 10.1007/BF02245122 · DOI
  165. Daston, 1958, Stylus maze performance of chronic schizophrenics taking chlorpromazine, Journal of Consulting Psychology, 22, 384, 10.1037/h0041643 · doi:10.1037/h0041643
  166. Daston, 1959, Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics, Journal of Clinical Psychology, 15, 106, 10.1002/1097-4679(195901)15:1<106::AID-JCLP2270150128>3.0.CO;2-E · doi:10.1002/1097-4679(195901)15:1<106::aid-jclp2270150128>3.0.co;2-e
  167. Davies, 1973, The use of chlorpromazine in schizophrenia, Nursing Times, 69, 1694
  168. Dean, 1967, Mefenamic acid and chlorpromazine in porphyria variegata, South African Medical Journal, 41, 925
  169. Denber, 1955, Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination, Journal of Nervous and Mental Diseases, 122, 463, 10.1097/00005053-195511000-00008 · doi:10.1097/00005053-195511000-00008
  170. Denber, 1956, Chlorpromazine in the treatment of mental illness. III. The problem of depression, American Journal of Psychiatry, 112, 1021, 10.1176/ajp.112.12.1021 · doi:10.1176/ajp.112.12.1021
  171. Denber, 1957, Chlorpromazine-diethazine in the treatment of depression, Diseases of the Nervous System, 18, 76
  172. Boer, 2000, Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia, Human Psychopharmacology, 15, 179, 10.1002/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N · DOI
  173. Desager, 1988, Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic, Psychopharmacology Berlin, 96, 63, 10.1007/BF02431534 · DOI
  174. Douglas, 1969, A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients, Journal of Clinical Pharmacology and The Journal of New Drugs, 9, 176
  175. Downing, 1963, Effect of phenothiazines on the thinking of acute schizophrenics, Perceptual and Motor Skills, 17, 511, 10.2466/pms.1963.17.2.511 · DOI
  176. Dube, 1981, Efficacy of lithium in schizophrenia, Indian Journal of Psychiatry, 23, 193
  177. Eitan, 1992, Effects of antipsychotic drugs on memory functions of schizophrenic patients, Acta Psychiatrica Scandinavica, 85, 74, 10.1111/j.1600-0447.1992.tb01446.x · DOI · Paper page
  178. Ekdawi, 1966, A controlled trial of anti-parkinson drugs in drug-induced parkinsonism, British Journal of Psychiatry, 112, 633, 10.1192/bjp.112.487.633 · doi:10.1192/bjp.112.487.633
  179. Elkes, 1954, Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients, British Medical Journal, 2, 560, 10.1136/bmj.2.4887.560 · DOI
  180. Feldman, 1956, A controlled, blind study of effects of thorazine on psychotic behavior, Bulletin of the Menninger Clinic, 20, 25
  181. Fink, 1958, Comparative study of chlorpromazine and insulin coma in therapy of psychosis, Journal of the American Medical Association, 166, 1846, 10.1001/jama.1958.02990150042009 · doi:10.1001/jama.1958.02990150042009
  182. Fink, 1965, Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders, Psychopharmacologia, 7, 27, 10.1007/BF00404162 · DOI
  183. Fleming, 1958, Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis, British Journal of Psychiatry, 104, 749
  184. Foote, 1958, Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics, British Journal of Psychiatry, 104, 201
  185. Forrest, 1967, The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo, Journal of Psychiatric Research, 5, 281, 10.1016/0022-3956(67)90016-7 · DOI
  186. Freed, 1956, Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine, American Journal of Psychiatry, 113, 22, 10.1176/ajp.113.1.22 · doi:10.1176/ajp.113.1.22
  187. Freedman, 1965, Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment, Journal of Personality and Social Psychology, 1, 310, 10.1037/h0021923 · doi:10.1037/h0021923
  188. Freeman, 1956, Effects of chlorpromazine and reserpine in chronic schizophrenic patients, Diseases of the Nervous System, 17, 213
  189. Freeman, 1956, Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A, Archives of Neurology and Psychiatry, 76, 500, 10.1001/archneurpsyc.1956.02330290044005 · doi:10.1001/archneurpsyc.1956.02330290044005
  190. Freeman, 1973, A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics, Diseases of the Nervous System, 34, 289
  191. Friedhoff, 1960, The effect of chlorpromazine on the variability of motor task performance in schizophrenics, Journal of Nervous and Mental Disease, 131, 110, 10.1097/00005053-196008000-00003 · doi:10.1097/00005053-196008000-00003
  192. Fromm, 1956, Controlled study on the value of chlorpromazine in allaying anxiety, Diseases of the Nervous System, 17, 16
  193. Gaitz, 1955, Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients, Psychiatric Research Reports, 1, 1984
  194. Galbrecht, 1968, Predicting response to phenothiazines: the right drug for the right patient, Journal of Nervous and Mental Disease, 147, 173, 10.1097/00005053-196808000-00009 · doi:10.1097/00005053-196808000-00009
  195. Galdi, 1988, Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics, Canadian Journal of Psychiatry, 33, 816, 10.1177/070674378803300906 · doi:10.1177/070674378803300906
  196. Gallant, 1963, The relationship between serotonin antagonism and tranquilizing activity, American Journal of Psychiatry, 119, 882, 10.1176/ajp.119.9.882 · doi:10.1176/ajp.119.9.882
  197. Gallant, 1967, BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine, Current Therapeutic Research, 9, 447
  198. Gardner, 1955, Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia, Psychiatric Research Reports, 1, 77
  199. Gardos, 1968, Trifluoperazine and chlorpromazine in combination and individually, Current Therapeutic Research Clinical and Experimental, 10, 609
  200. Gardos, 1976, Maintenance antipsychotic therapy: is the cure worse than the disease?, American Journal of Psychiatry, 133, 32, 10.1176/ajp.133.1.32 · DOI · Paper page

200 of 481 shown

Cited by

See all 171

Metadata

Authors
Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2014-01-06
Volume
2015
Issue
11
Pages
CD000284-CD000284
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1910485579
Cited by
171
References
11
FWCI
8.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chlorpromazine versus placebo for schizophrenia. https://app.cochat.ai/papers/10.1002/14651858.cd000284.pub3
The paper
Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K. (2014). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000284.pub3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.